Custom Search


Saturday 01 May 2004

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.

By: Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, Alhusein Q, Antal D, Salles G, Coiffier B.

Bone Marrow Transplant 2004 May;33(9):921-3

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.

Use of this site is subject to the following terms of use